{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:23:41Z","timestamp":1779888221083,"version":"3.53.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["PTQ2018\\u2013009760"],"award-info":[{"award-number":["PTQ2018\\u2013009760"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.biopha.2026.119248","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T20:26:27Z","timestamp":1773865587000},"page":"119248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Metformin enhances response to chemotherapy combined with immunotherapy in a triple negative breast cancer in vivo model"],"prefix":"10.1016","volume":"198","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8931-0624","authenticated-orcid":false,"given":"Angelo","family":"G\u00e1mez-Pozo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luz","family":"Vega-Clemente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Trilla-Fuertes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"L\u00f3pez-Camacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3726-050X","authenticated-orcid":false,"given":"Fernando","family":"Becerril-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Alonso-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"L\u00f3pez-Vacas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Lalanda-Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Zamora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Garc\u00eda-Arranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan \u00c1ngel","family":"Fresno Vara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.biopha.2026.119248_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157368","article-title":"Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection","volume":"11","author":"Lehmann","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.biopha.2026.119248_bib2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119248_bib3","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1080\/14712598.2020.1769063","article-title":"Atezolizumab in the treatment of metastatic triple-negative breast cancer","volume":"20","author":"P\u00e9rez-Garc\u00eda","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2026.119248_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13543784.2019.1552255","article-title":"Atezolizumab for the treatment of triple-negative breast cancer","volume":"28","author":"Heimes","year":"2019","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"10257","key":"10.1016\/j.biopha.2026.119248_bib5","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial","volume":"396","author":"Mittendorf","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.biopha.2026.119248_bib6","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119248_bib7","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40265-020-01295-y","article-title":"Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer","volume":"80","author":"Kang","year":"2020","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.biopha.2026.119248_bib8","doi-asserted-by":"crossref","first-page":"9645","DOI":"10.18632\/oncotarget.24047","article-title":"Molecular characterization of breast cancer cell response to metabolic drugs","volume":"9","author":"Trilla-Fuertes","year":"2018","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.biopha.2026.119248_bib9","doi-asserted-by":"crossref","first-page":"909","DOI":"10.4161\/cc.8.6.7933","article-title":"Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro","volume":"8","author":"Alimova","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.biopha.2026.119248_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112844","article-title":"Synergistic effect of antimetabolic and chemotherapy drugs in triple-negative breast cancer","volume":"149","author":"L\u00f3pez-Camacho","year":"2022","journal-title":"Biomed. Pharm."},{"issue":"19","key":"10.1016\/j.biopha.2026.119248_bib11","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1158\/0008-5472.CAN-09-2994","article-title":"Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission","volume":"69","author":"Hirsch","year":"2009","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.biopha.2026.119248_bib12","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1158\/0008-5472.CAN-10-3471","article-title":"Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types","volume":"71","author":"Iliopoulos","year":"2011","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.biopha.2026.119248_bib13","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.tips.2020.01.003","article-title":"Context-Dependent Pharmacological Effects of Metformin on the Immune System","volume":"41","author":"Marcucci","year":"2020","journal-title":"Trends Pharm. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119248_bib14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1158\/2326-6066.CIR-16-0103","article-title":"Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia","volume":"5","author":"Scharping","year":"2017","journal-title":"Cancer Immunol. Res"},{"issue":"4","key":"10.1016\/j.biopha.2026.119248_bib15","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.molcel.2018.07.030","article-title":"Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1","volume":"71","author":"Cha","year":"2018","journal-title":"Mol. Cell"},{"issue":"6","key":"10.1016\/j.biopha.2026.119248_bib16","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1073\/pnas.1417636112","article-title":"Immune-mediated antitumor effect by type 2 diabetes drug, metformin","volume":"112","author":"Eikawa","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2026.119248_bib17","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ebiom.2017.10.009","article-title":"Attenuation of CD4(+)CD25(+) Regulatory T Cells in the Tumor Microenvironment by Metformin, a Type 2 Diabetes Drug","volume":"25","author":"Kunisada","year":"2017","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.biopha.2026.119248_bib18","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s41419-025-07636-7","article-title":"Addition of metformin to anti-PD-1\/PD-L1 drugs activates anti-tumor immune response in peripheral immune cells of NSCLC patients","volume":"16","author":"Amato","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biopha.2026.119248_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2018.08.748","article-title":"Retrospective Descriptive Analysis of Metformin with Atezolizumab in Advanced Non-Small Cell Lung Cancer in The OAK Trial","author":"Pietras","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119248_bib20","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharm. Rev."},{"key":"10.1016\/j.biopha.2026.119248_bib21","series-title":"CompuSyn for drug combinations and from general dose-effect analysis. User\u00b4s Guide. A computer program for quantitation of synergism and antagonism in drug combinations and the determination of IC50, ED50 and LD50 values","author":"Chou","year":"2007"},{"issue":"1","key":"10.1016\/j.biopha.2026.119248_bib22","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1038\/s41467-023-40398-4","article-title":"Combined PD-L1\/TGF\u03b2 blockade allows expansion and differentiation of stem cell-like CD8 T cells in immune excluded tumors","volume":"14","author":"Castiglioni","year":"2023","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.biopha.2026.119248_bib23","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s10549-013-2735-3","article-title":"Cure of metastatic growth of EMT6 tumor cells in mice following manipulation of CD200:CD200R signaling","volume":"142","author":"Gorczynski","year":"2013","journal-title":"Breast Cancer Res Treat."},{"issue":"1","key":"10.1016\/j.biopha.2026.119248_bib24","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1038\/s41467-019-09015-1","article-title":"Primary tumor-induced immunity eradicates disseminated tumor cells in syngeneic mouse model","volume":"10","author":"Piranlioglu","year":"2019","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.biopha.2026.119248_bib25","doi-asserted-by":"crossref","first-page":"160","DOI":"10.5625\/lar.2018.34.4.160","article-title":"Mouse models of breast cancer in preclinical research","volume":"34","author":"Park","year":"2018","journal-title":"Lab Anim. Res"},{"issue":"11","key":"10.1016\/j.biopha.2026.119248_bib26","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1158\/2159-8290.CD-18-0044","article-title":"Mouse Models for Cancer Immunotherapy Research","volume":"8","author":"Olson","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2026.119248_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172541","article-title":"Metformin suppresses cancer cell growth in endometrial carcinoma by inhibiting PD-L1","volume":"859","author":"Xue","year":"2019","journal-title":"Eur. J. Pharm."},{"issue":"11","key":"10.1016\/j.biopha.2026.119248_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002614","article-title":"Metformin reduces PD-L1 on tumor cells and enhances the anti-tumor immune response generated by vaccine immunotherapy","volume":"9","author":"Munoz","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2026.119248_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.762523","article-title":"Metformin Downregulates PD-L1 Expression in Esophageal Squamous Cell Catrcinoma by Inhibiting IL-6 Signaling Pathway","volume":"11","author":"Lu","year":"2021","journal-title":"Front Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119248_bib30","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2026.119248_bib31","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1158\/0008-5472.CAN-14-1937","article-title":"Combined label-free quantitative proteomics and microRNA expression analysis of breast cancer unravel molecular differences with clinical implications","author":"G\u00e1mez-Pozo","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2026.119248_bib32","unstructured":"K. Johnson-Arbor, R. Dubey, Doxorubicin., 2023 Aug 8."},{"issue":"19","key":"10.1016\/j.biopha.2026.119248_bib33","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1001\/jama.2019.3805","article-title":"Metformin in 2019","volume":"321","author":"Flory","year":"2019","journal-title":"JAMA"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226002817?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226002817?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:57:08Z","timestamp":1779245828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226002817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":33,"alternative-id":["S0753332226002817"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119248","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metformin enhances response to chemotherapy combined with immunotherapy in a triple negative breast cancer in vivo model","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119248","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119248"}}